Dimerix Limited

Equities

DXB

AU000000DXB7

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-07-17 EDT			5-day change	1st Jan Change
0.54 ^AUD	+5.88%		+22.73%	+163.41%

07-04	Dimerix to Recruit Adolescents for Kidney Drug Study; Shares Decline 7%	MT
05-29	Euroz Hartleys Adjusts Dimerix’s Price Target to AU$0.86 From AU$0.80, Keeps at Speculative Buy	MT

Dimerix Limited announced that it expects to receive AUD 2.03 million in funding

January 18, 2018

Dimerix Limited (ASX:DXB) announced a private placement of 16,926,753 common shares at an issue price of AUD 0.12 per share for gross proceeds of AUD 2,031,210.36 on January 19, 2018. The transaction is expected to close on February 28, 2018.

Latest news about Dimerix Limited

Dimerix to Recruit Adolescents for Kidney Drug Study; Shares Decline 7%	07-03	MT
Euroz Hartleys Adjusts Dimerix’s Price Target to AU$0.86 From AU$0.80, Keeps at Speculative Buy	05-29	MT
Dimerix Signs License Deal for Kidney Disease Medication in the Middle East	05-27	MT
Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication	04-30	MT
Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter	04-22	MT
Euroz Hartleys Starts Dimerix at Speculative Buy With AU$0.80 Price Target	04-19	MT
Dimerix Raises AU$20 Million for Kidney Disease Study	03-12	MT
Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better than Placebo	03-10	MT
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-25	CI
Dimerix Limited Announces Appointment of Mark Diamond as Director	11-30	CI
Dimerix Secures Investigational New Drug Approval for Kidney Disease Medication in China; Shares Rally 11%	11-27	MT
Dimerix Appoints Nonexecutive Chair	11-19	MT
Dimerix Receives AU$10.7 Million Upfront Payment for Commercialization Rights	11-07	MT
Dimerix Appoints Medical Chief	23-10-22	MT
Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer	23-10-22	CI
Softer US Employment Data End Australian Shares' Three-Day Losing Streak	23-10-05	MT
Dimerix Surges 154% After Securing License Deal for Kidney Disease Drug	23-10-05	MT
Dimerix Secures Conditional US FDA Clearance for Kidney Medication Brand Name	23-09-25	MT
Dimerix Secures Regulatory Nod to Conduct Kidney Disease Drug Trial in Malaysia	23-09-22	MT
Dimerix Secures AU$9 Million R&D Tax Rebate; Shares Rise 3%	23-09-12	MT
Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-29	CI
Dimerix Secures Approval for Pediatric Kidney Disease Plan in Europe	23-07-05	MT
Dimerix Secures Study Design Approval in China for Phase Three Kidney Disease Trial; Shares Rise 6%	23-07-02	MT
Dimerix Raising AU$12 Million to Continue Clinical Program; Shares Down 7%	23-05-03	MT
Dimerix Limited Appoints Clinton Snow New Non-Executive Director to the Board, Effective 01 May 2023	23-04-30	CI

Chart Dimerix Limited

Duration

Period

More charts

Company Profile

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. It develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The Company is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DIMERIX LIMITED	+163.41%	189M
MODERNA, INC.	+24.74%	47.96B
IQVIA HOLDINGS INC.	-0.47%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	31.6B
ICON PUBLIC LIMITED COMPANY	+17.96%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.56B
MEDPACE HOLDINGS, INC.	+42.56%	14.14B
BIO-TECHNE CORPORATION	+1.46%	12.58B

Other Biotechnology & Medical Research